Idiopathic pulmonary fibrosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• AKT 0
• PI3K 0
• mTOR 0
• AMPK 0
• TP53 0
• HIF-1 0
• NRF2 0
• MAPK 0
• STAT3 0
• MMP-9 0
• PPAR 0
• YAP 0
• IL-1 0
• PDE4 0
• BCL-2 0
• HMGB1 1
• IL-17 0
• JAK 0
• MEK 0
• METTL3 0
• NLRP3 0
• PTEN 0
• STING 0
• TLR4 0
• CTNNB1 0
• EGFR 0
• ERK 0
• HSP90 0
• PD-1 0
• PD-L1 0
• PINK1 0
• ACE2 0
• APOE 0
• ATM 0
• BDNF 0
• BRD4 0
• CD20 0
• CD47 0
• CDKN2A 0
• COX-2 0
• CSF1R 0
• CXCR4 0
• DLL3 0
• ESR1 0
• FGFR 0
• GLP-1 0
• GPX4 0
• HDAC 0
• IL-6 0
• JNK 0
• NTRK 0
• PDGFR 0
• PKM2 0
• SIRT1 0
• STK11 0
• TERT 0
• TFEB 0
• TNF 0
• TSLP 0
• VEGF 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK2

  IMPLEMENT-IPF: Improving Management Practices and Leveraging Expertise for iNitiating Treatment in Idiopathic Pulmonary Fibrosis (IPF)

  Durham Va Medical Center· Durham, United States· until Sept 2031

• NIH NHLBI · F32

  Deciphering the Epigenetic Regulation of Airway Basal Cell Identity in Disease and Aging

  Massachusetts General Hospital· Boston, United States· US$82,348 awarded in fiscal year 2026· until Sept 2029

• NIH NCI · R01

  Integrating AI and Deep Mutational Scanning to Predict the Cancer-Promoting Effect of Shelterin Mutations

  University of California Berkeley· Berkeley, United States· US$2,197,943 awarded in fiscal year 2026· until Aug 2029

• NIH NHLBI · P01

  Viral-mediated immunological niche facilitates lung fibrosis

  Cedars-Sinai Medical Center· Los Angeles, United States· US$2,604,104 awarded in fiscal year 2026· until Jun 2031

• NIH NIAID · DP2

  Pathogenic B-cell programs in lung TLSs as drivers of post-tuberculosis lung disease

  Massachusetts General Hospital· Boston, United States· US$485,250 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  COMPrehensive framework for dAta-driven chemical teSting Solutions (COMPASS)

  Tampereen Korkeakoulusaatio Sr· Tampere, Finland· EU contribution €242,117· until Aug 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Uncovering Genetic Rescue and Functional Rebalancing in Telomeropathies Through Genome Editing and High-Resolution Screening (REBALANCE)

  Genome Research Limited Lbg· Saffron Walden, United Kingdom· EU contribution €2,496,154· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  GENOME ENGINEERING OF MACROPHAGES TO MEDIATE REGENERATION OF THE FIBROTIC LUNG (BREATH)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €9,988,380· until Sept 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Determining the mechanistic role of gremlin 1 in the profibrotic activation of monocyte-derived macrophages and in the pathogenesis of idiopathic pulmonary fibrosis (IPF-MDM-GREMLIN)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €268,569· until Jul 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A peptide targeting p21-CDK4 interaction for treatment of pulmonary fibrosis (FibroPep)

  Weizmann Institute of Science· Rehovot, Israel· EU contribution €150,000· until Dec 2027

10 of 482 running projects, newest first. Listed amounts together: US$286.8m + €37.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 19
• Organoids 4
• Mendelian Randomization Analysis 20
• CRISPR-Cas Systems 4
• Gene Expression Profiling 50
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 2
• Exome Sequencing 2
• Proteomics 21
• Metabolomics 10
• Mass Spectrometry 1
• Flow Cytometry 3
• Immunohistochemistry 5
• Liquid Biopsy 1
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 4
• Machine Learning 28
• Deep Learning 9
• Cohort Studies 38
• Genome-Wide Association Study 19

See which targets of this disease your abstract mentions, and go to the people working on them.